Sarepta Therapeutics, Inc.
SRPT
$16.66
$0.261.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -277.84% | -635.38% | 2,947.86% | -1,338.98% | 248.37% |
| Total Depreciation and Amortization | -49.76% | 88.15% | 24.33% | 14.11% | -8.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.77% | 71.83% | -90.98% | 218.41% | 23.13% |
| Change in Net Operating Assets | 371.62% | 86.51% | 209.16% | 14.51% | 16.83% |
| Cash from Operations | 42.54% | 79.37% | 1,649.01% | -141.01% | 268.41% |
| Capital Expenditure | 90.57% | 38.45% | -9.01% | -34.54% | -100.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -87.56% | 378.86% | 192.28% | -198.52% | 1,870.12% |
| Cash from Investing | -87.41% | 280.40% | 132.69% | -233.08% | 1,287.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -51,566.18% | -- | -- | -- | -- |
| Issuance of Common Stock | -91.70% | 54.21% | -96.24% | -29.17% | 90.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -109.67% | -- | -- | -- | -- |
| Cash from Financing | -180.03% | -956.22% | -159.66% | -43.67% | 2,421.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -79.21% | 153.84% | 717.69% | -75,526.58% | 873.16% |